| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23001 |
| Drug | Difelikefalin |
| Brand | Kapruvia® |
| Indication | For the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis. |
| Assessment Process | |
| Rapid review commissioned | 09/01/2023 |
| Rapid review completed | 02/02/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of difelikefalin compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/03/2023 |
| Pre-submission consultation with Applicant | 16/05/2023 |
| Full submission received from Applicant | 12/09/2023 |
| Preliminary review sent to Applicant | 24/11/2023 |
| NCPE assessment re-commenced | 21/12/2023 |
| Factual accuracy sent to Applicant | 22/01/2024 |
| NCPE assessment re-commenced | 29/01/2024 |
| NCPE assessment completed | 06/02/2024 |
| NCPE assessment outcome | The NCPE recommends that difelikefalin be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
